Produção e padronização dos antígenos de Paracoccidioides brasiliensis (Pb), Histoplasma capsulatum (Hc) e Aspergillus fumigatus (Af) para uso no imunodiagnóstico: comparação entre as técnicas de imunodifusão e imunoeletroosmoforese

Foram produzidos antígenos solúveis de P. brasiliensis, H. capsulatum e A. fumigatus e padronizados nas técnicas de imunodifusão dupla (IDD) e imunoeletroosmoforese (IEOF). A especificidade dos antígenos foi testada utilizando-se 96 soros de pacientes com paracoccidioidomicose, histoplasmose, aspergilose, candidíase sistêmica, esporotricose, tuberculose, neoplasia pulmonar, leishmaniose tegumentar e visceral e em 18 indivíduos sadios. Na IDD, a especificidade foi de 100% usando-se como critério de positividade linhas de precipitação com identidade total com soro de referência. Entretanto na IEOF, a especificidade variou de acordo com o antígeno testado, sendo observadas reações cruzadas com antígeno de P. brasiliensis frente a soros de pacientes com histoplasmose (16,7%) e leishmaniose tegumentar (10%) e com antígeno de H. capsulatum frente a soros de pacientes com paracoccidioidomicose (31,8%) e leishmaniose tegumentar (10%). Ambas as técnicas mostraram a mesma sensibilidade para o sorodiagnóstico de paracoccidioidomicose, histoplasmose e aspergilose, respectivamente 100%, 83,3% e 100%. A grande sensibilidade e especificidade da IDD observadas nos soros desses pacientes, aliadas à fácil reprodutibilidade e baixo custo, fazem esta técnica muito apropriada como procedimento de rotina, para a triagem de pacientes sintomáticos respiratórios.

Sagor : af Z. Topelius - [Bilder] - Första samlingen (0001)

1 Helsingfors : A. W. Gröndahl 1847

Skandinaviens fiskar. Förra delen, Text / målade af Wilh. von Wright ; med text af B. Fries, C. U. Ekström och C. Sundevall.

Von Wrightin taitelijaveljeksistä Wilhelm v. Wright (1810-1887) muutti Ruotsiin 18-vuotiaana avustaakseen vanhempaa veljeään Magnusta SKANDINAVIENS FÅGLAR -teoksen (ks. kohde 258) valmistamisessa. Wilhelm jäi pysyvästi Ruotsiin ja ryhtyi työskentelemään Kuninkaallisen tiedeakatemian piirtäjänä. Vuonna 1836 alkoi ilmestyä laaja kalakuvasto SKANDINAVIENS FISKAR, johon hän oli laatinut kuvat ja eläintieteilijät C. U. Ekström, B. F. Fries ja C. J. Sundevall kirjoittaneet tekstit. Tästä teoksesta tuli v. Wrightin kuvitustöistä merkittävin ja korkeatasoisin. Myöhemmin v. Wright toimi Bohuslänin kalastuksentarkastajan virassa, mutta halvaantui loppuelämäkseen yli kolmenkymmenen vuoden ajaksi.

Förra delen, om Gamle Carleby, ... : ... under ... Pehr Kalms inseende ... och almen granskning understäld i Åbo Academies öfre sal, den 19 Julii efter m. 1754, af Jacob Chydenius, Jac. son, österbotninge.

Dedicated to: Jacob Chydenius.

Stadgar för Djurskyddsföreningen i Iittis, Jaala och Artsjö socknar i Perno härad af Nylands län

11 x 17 cm

Öfversigt af Finlands litteratur af Sven Gabriel Elmgren, Ifrån år 1542 till 1770

Pro munere = virkaväitöskirja.

Handkarta öfver Finland för skolorna af R. Hult

1 kartta :, vär. ;, 62,8 x 46,5 cm, lehti 71 x 55 cm

Suomenmaan kartta Karta öfver Stor-furstendömet Finland med stöd af de tillförlitligaste karta verk och officiella väga-uppgifter, meddelande af samteliga länestyrelserne i landet, äfvensom andra bidrag författad af Berndt Ad. Lindeman

1 kartta :, vär. ;, 119 x 67 cm, kansi 26 x 18 cm

Karta öfver storfurstendömet Finland efter nya tillförlitliga källor och med särskildt begagnande af general stabens original-kartor utgiftven år 1860 af öfverste Georg Alfthan /

1 kartta :, vär. ;, 72,5 x 47,4 cm, lehti 83 x 58 cm

Karta öfver landswägarne uti Sverige och Norrige samt en del af Dannemark

Kartta kuuluu A. E. Nordenskiöldin kokoelmaan

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF

Background In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). We aimed to investigate whether the efficacy and safety of rivaroxaban compared with warfarin is consistent among the subgroups of patients with and without previous stroke or transient ischaemic attack (TIA). Methods In ROCKET AF, patients with AF who were at increased risk of stroke were randomly assigned (1:1) in a double-blind manner to rivaroxaban 20 mg daily or adjusted dose warfarin (international normalised ratio 2-0-3.0). Patients and investigators were masked to treatment allocation. Between Dec 18,2006, and June 17,2009,14 264 patients from 1178 centres in 45 countries were randomly assigned. The primary endpoint was the composite of stroke or non-CNS systemic embolism. In this substudy we assessed the interaction of the treatment effects of rivaroxaban and warfarin among patients with and without previous stroke or TIA. Efficacy analyses were by intention to treat and safety analyses were done in the on-treatment population. ROCKET AF is registered with ClinicalTrials.gov, number NCT00403767. Findings 7468 (52%) patients had a previous stroke (n=4907) or TIA (n=2561) and 6796 (48%) had no previous stroke or TIA. The number of events per 100 person-years for the primary endpoint in patients treated with rivaroxaban compared with warfarin was consistent among patients with previous stroke or TIA (2.79% rivaroxaban vs 2.96% warfarin; hazard ratio [HR] 0-94,95% CI 0.77-1.16) and those without (1.44% vs 1.88%; 0.77, 0.58-1-01; interaction p=0.23). The number of major and non-major clinically relevant bleeding events per 100 person-years in patients treated with rivaroxaban compared with warfarin was consistent among patients with previous stroke or TIA (13.31% rivaroxaban vs 13.87% warfarin; HR 0.96,95% CI 0.87-1-07) and those without (16.69% vs 15.19%; 1.10, 0.99-1.21; interaction p=0.08). Interpretation There was no evidence that the relative efficacy and safety of rivaroxaban compared with warfarin was different between patients who had a previous stroke or TIA and those who had no previous stroke or TIA. These results support the use of rivaroxaban as an alternative to warfarin for prevention of recurrent as well as initial stroke in patients with AF.